Prognostic factors for mature natural killer (NK) cell neoplasms: aggressive NK cell leukemia and extranodal NK cell lymphoma, nasal type

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1032-1040

  Suzuki, R ^a   Suzumiya, J ^b   Yamaguchi, M ^c   Nakamura, S ^d   Kameoka, J ^e   Kojima, H ^f   Abe, M ^g   Kinoshita, T ^d   Yoshino, T ^h   Iwatsuki, K ⁱ   Kagami, Y ^j   Tsuzuki, T ^k   Kurokawa, M ^l   Ito, K ^m   Kawa, K ⁿ   Oshimi, K ^o  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^h Departments of Pathology   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

^j AICHI CANCER CENTER HOSPITAL   (Japan)

^k NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^l UNIVERSITY OF MIYAZAKI   (Japan)

^m NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

ⁿ RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^o JUNTENDO UNIVERSITY   (Japan)

more..

Author keywords

CD16; Leukemia; Lymphoma; Natural killer cell; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AGGRESSIVE NK CELL LEUKEMIA; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN TISSUE; INTESTINE LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; SKIN LYMPHOMA; TREATMENT OUTCOME;

EID: 77953227669     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp418     Document Type: Article

References (58)

1. Jaffe ES. Classification of natural killer (NK) cell and NK-like T-cell malignancies. Blood 1996; 87: 1207-1210.
2. Oshimi K. Leukemia and lymphoma of natural killer lineage cells. Int J Hematol 2003; 78: 18-23.
3. Suzuki R, Takeuchi K, Ohshima K et al. Extranodal NK/T-cell lymphoma: diagnosis and treatment cues. Hematol Oncol 2008; 26: 66-72.
4. Chan JKC, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001; 204-207.
5. Chan JKC, Wong KF, Jaffe ES et al. Aggressive NK-cell leukemia. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds), World Health Organization Classification of Tumors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2001; 198-200.
6. Lymphoma Study Group of Japanese Pathologists. The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 2000; 50: 696-702.
7. Au WY, Ma SY, Chim CS et al. Clinicopathologic features and treatment outcome of mature T-cell and natural killer cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 2005; 16: 206-214.
8. Ko YH, Kim CW, Park CS et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Cancer 1998; 83: 806-812.
9. Chen CY, Yao M, Tang JL et al. Chromosomal abnormalities of 200 Chinese patients with non-Hodgkin's lymphoma in Taiwan: with special reference to T-cell lymphoma. Ann Oncol 2004; 15: 1091-1096.
10. Yamaguchi M, Ohno T, Oka K et al. Discordant reaction of Leu4 and rabbit anti-human CD3 epsilon in sinonasal 'T'-cell lymphoma. Int J Hematol 1993; 59: 25-30.
11. Suzumiya J, Takeshita M, Kimura N et al. Expression of adult and fetal natural killer cell markers in sinonasal lymphomas. Blood 1994; 83: 2255-2260.
12. Chan JK, Tsang WY, Pau MY. Discordant CD3 expression in lymphomas when studied on frozen and paraffin sections. Hum Pathol 1995; 26: 1139-1143.
13. Emile JF, Boulland ML, Haioun C et al. CD5-CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 1996; 87: 1466-1473.
14. Harabuchi Y, Yamanaka N, Kataura A et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990; 335: 128-130.
15. Jaffe ES, Chan JK, Su IJ et al. Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis, and epidemiology. Am J Surg Pathol 1996; 20: 103-111.
16. Kawa-Ha K, Ishihara S, Ninomiya T et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest 1989; 84: 51-55.
17. Oshimi K, Yamada O, Kaneko T et al. Laboratory findings and clinical courses of 33 patients with granular lymphocyte-proliferative disorders. Leukemia 1993; 7: 782-788.
18. Suzuki R, Suzumiya J, Nakamura S et al. Aggressive natural killer (NK)-cell leukemia revisited: large granular lymphocyte leukemia of cytotoxic NK cells. Leukemia 2004; 18: 763-770.
19. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004; 103: 216-221.
20. Kim TM, Park YH, Lee SY et al. Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal type. Blood 2005; 106: 3785-3790.
21. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.
22. Suzuki R, Nakamura S, Suzumiya J et al. Blastic natural killer cell lymphoma/ leukemia (CD56-positive blastic tumor): prognostication and categorization according to anatomic sites of involvement. Cancer 2005; 104: 1022-1031.
23. Oshimi K, Kawa K, Nakamura S et al. NK-cell neoplasms in Japan. Hematology 2005; 10: 237-245.
24. Suzuki R, Kagami Y, Takeuchi K et al. Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null cell phenotype. Blood 2000; 96: 2993-3000.
25. + myeloid/natural killer cell precursor acute leukemia: a distinct hematolymphoid disease entity. Blood 1997; 90: 2417-2428.
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
27. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-2479.
28. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 1244-1253.
29. Suzuki R, Suzumiya J, Nakamura S et al. Hematopoietic stem cell transplantation for natural killer-cell lineage neoplasms. Bone Marrow Transplant 2006; 37: 425-431.
30. Lee J, Au WY, Park MJ et al. Autologous hematopoietic stem cell transplantation in extranodal NK/T-cell lymphoma: a multinational, multicenter, matched controlled study. Biol Blood Marrow Transplant 2008; 14: 1356-1364.
31. Chan JKC, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 1997; 89: 4501-4513.
32. Rodriguez J, Romaguera JE, Manning J et al. Nasal-type T/NK lymphomas: a clinicopathologic study of 13 cases. Leuk Lymphoma 2000; 39: 139-144.
33. Mraz-Gernhard S, Natkunam Y, Hoppe RT et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: an increasingly recognized entity with an aggressive course. J Clin Oncol 2001; 19: 2179-2188.
34. Ng SB, Lai KW, Murugaya S et al. Nasal-type extranodal natural killer/T-cell lymphomas: a clinicopathologic and genotypic study of 42 cases in Singapore. Mod Pathol 2004; 17: 1097-1107.
35. Ko YH, Cho EY, Kim JE et al. NK and NK-like T-cell lymphoma in extranasal sites: a comparative clinicopathological study according to site and EBV status. Histopathology 2004; 44: 480-489.
36. Lee J, Kim WS, Park YH et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome. Br J Cancer 2005; 92: 1226-1230.
37. Quintanilla-Martinez L, Jaffe ES. Aggressive NK cell lymphomas: insights into the spectrum of NK cell derived malignancies. Histopathology 2000; 37: 372-374.
38. Siu LL, Wong KF, Chan JK, Kwong YL. Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations. Am J Pathol 1999; 155: 1419-1425.
39. Nakashima Y, Tagawa H, Suzuki R et al. Genome-wide array-based comparative genomic hybridization of natural killer cell lymphoma/leukemia: different genomic alteration patterns of aggressive NK-cell leukemia and extranodal NK/T-cell lymphoma, nasal type. Genes Chromosomes Cancer 2005; 44: 247-255.
40. Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349-352.
41. Kim GE, Cho JH, YangWI et al. Angiocentriclymphomaoftheheadandneck:patterns of systemic failure after radiation treatment. J Clin Oncol 2000; 18: 54-63.
42. Li CC, Tien HF, Tang JL et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100: 366-375.
43. Isobe K, Uno T, Tamaru J et al. Extranodal natural killer/T-cell lymphoma, nasal type: the significance of radiotherapeutic parameters. Cancer 2006; 106: 609-615.
44. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21-26.
45. Yamaguchi M, Kita K, Miwa H et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer 1995; 76: 2351-2356.
46. Egashira M, Kawamata N, Sugimoto K et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999; 93: 599-606.
47. Suzuki R. Leukemia and lymphoma of natural killer cells. J Clin Exp Hematop 2005; 45: 51-70.
48. Yamaguchi M, Oguchi M, Tobinai K et al. Phase I/II study of concurrent chemoradiotherapy for newly-diagnosed, localized nasal NK/T-cell lymphoma: results of a phase I portion of JCOG0211-DI. Blood 2005; 106: 754a (Abstr 2685).
49. Au WY, Lie AK, Liang R et al. Autologous stem cell transplantation for nasal NK/ T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 1673-1676.
50. Murashige N, Kami M, Kishi Y et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 130: 561-567.
51. Kim HJ, Bang SM, Lee J et al. High-dose chemotherapy with autologous stem cell transplantation in extranodal NK/T-cell lymphoma: a retrospective comparison with non-transplantation cases. Bone Marrow Transplant 2006; 37: 819-824.
52. Oshimi K. Progress in understanding and managing natural killer-cell malignancies. Br J Haematol 2007; 139: 532-544.
53. Yong W, Zheng W, Zhang Y et al. L-asparaginase-based regimen in the treatment of refractory midline nasal/nasal-type T/NK-cell lymphoma. Int J Hematol 2003; 78: 163-167.
54. Obama K, Tara M, Niina K. L-asparaginase-based induction therapy for advanced extranodal NK/T-cell lymphoma. Int J Hematol 2003; 78: 248-250.
55. Matsumoto Y, Nomura K, Kanda-Akano Y et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 2003; 44: 879-882.
56. Yamaguchi M, Suzuki R, Kwong YL et al. Phase I study of dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 2008; 99: 1016-1020.
57. Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. Blood 2009; 113: 3931-3937.
58. Suzuki R, Suzumiya J, Oshimi K. Differences between nasal and extranasal NK/T-cell lymphoma. Blood 2009; 113: 6261-6262.